Trivalent Inactivated Influenza Vaccine (Inactivated Subunit) (TIIV)
AGRIFLU®
Supplier: Seqirus Canada Inc.

INDICATIONS:
- See 2020/21 Seasonal Influenza Vaccine Eligibility
- Intended for use in eligible individuals 18 years of age and older.
- May be used in children 6 months-17 years of age if a quadrivalent influenza vaccine is unavailable.
- Use for individuals with a known hypersensitivity to thimerosal.

The vaccine is not approved for use in those less than 6 months of age.

DOSES AND SCHEDULE:
Adults 18 years of age and older: 1 dose given as 0.5 mL IM.

Children and Adolescents 9-17 years of age (inclusive): 1 dose given as 0.5 mL IM.

Children 6 months-8 years of age (inclusive): 1 or 2 doses given as 0.5 mL IM.

Children under 9 years of age who have not previously received any seasonal influenza vaccine require 2 doses given 4 weeks apart. If the child has received 1 or more doses in any previous season, only a single dose is required. For children requiring 2 doses within the season, QIIV or TIIV may be given interchangeably with LAIV-Q with either product used for the 1st or 2nd dose if LAIV-Q is not available.

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES AND RE-IMMUNIZATION:
Annually.

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of any type of influenza vaccine or to any component of AGRIFLU®.
2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a previous dose of influenza vaccine without another cause being identified.
3. Receipt of a CTLA-4 inhibitor (e.g., ipilimumab) alone or in combination with other checkpoint inhibitors for the treatment of cancer. Inactivated influenza vaccine should be given 4-6 weeks before starting treatment or 4-6 weeks after the last dose. For more specific details refer to the BC Cancer Influenza vaccine recommendations.
Trivalent Inactivated Influenza Vaccine (Inactivated Subunit) (TIIV)
AGRIFLU®    Supplier: Seqirus Canada Inc.

PRODUCT COMPONENTS:
Potential allergens: egg proteins, ovalbumin, polysorbate 80, neomycin, kanamycin, hydrocortisone (See SPECIAL CONSIDERATIONS).
Other components: potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, formaldehyde, cetyltrimethylammonium bromide (CTAB), barium, citrates.

PRECAUTIONS:
Severe oculo-respiratory syndrome (ORS) after a previous dose of influenza vaccine. A

SPECIAL CONSIDERATIONS:
Egg allergic individuals (including those who have experienced anaphylaxis following egg ingestion) can be immunized with inactivated or live attenuated influenza vaccine in any setting attended by immunization service providers who are following standard vaccine administration practice. B

ADVERSE EVENTS:
Local: pain, induration, redness, swelling.
Systemic: headache, myalgia, malaise, fatigue. Fewer than 1 in 20 people may develop oculo-respiratory syndrome (ORS). Symptoms include red eyes, a cough, and/or sore throat and/or hoarseness.

A See Safety Issues Applicable to Influenza Vaccines, 2. Oculo-Respiratory Syndrome (ORS).